Inhibition of STAT3 increased the sensitivity of K562/A02 cells to adriamycin by down-regulating mdr1. All these findings suggested that STAT3 signaling may be an interesting target for reverting (or preventing) chemoresistance in myeloid leukemia. Here, STAT3 is linked to myeloid leukemia.